Sullivan John James sold $800K of MLAB

Sullivan John James sold 7,093 shares of MESA LABORATORIES INC /CO/ (MLAB) at $112.80 ($0.80M total) on 2026-08-13.

Original reporting
SEC EDGAR · Sullivan John James
Published Aug 17, 2026, 4:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 4:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest information is the director’s open-market sale size and price ($112.80/share) disclosed in the filing; it can influence short-term sentiment but does not provide new fundamentals.

02

Market read

Traders may monitor insider selling as a sentiment input, but this specific disclosure lacks any fundamental catalyst in the provided text.

03

What to watch

The text does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context like total compensation, tax events, or prior sale history.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction report for MESA LABORATORIES INC /CO/ (MLAB).

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

MLAB director Sullivan John James sold 7,093 shares in an open-market transaction worth about $800,090, per a new Form 4 filing.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine Form 4 open-market sale by a director, with no 10b5-1 plan indicated and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; the disclosure is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or liquidity needs and may not signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • MLAB

    MESA LABORATORIES INC /CO/, issuer of the Form 4 insider sale.

  • Sullivan John James

    Director who sold 7,093 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality